Diabetic nephropathy medical therapy: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
 
(One intermediate revision by one other user not shown)
Line 7: Line 7:


==Medical Therapy==
==Medical Therapy==
Medical treatment in diabetic nephropathy is aimed at slowing the progression of [[albuminuria]]. Interventions include
See [[Diabetic nephropathy secondary prevention]]
* Improved glycemic control
* Strict control of [[blood pressure]]
* Treatment of [[dyslipidemia]]
* [[Angiotensin Converting Enzyme Inhibitor|Angtiotensin converting enzyme inhibitor]] ([[ACEI]])
** Preffered regimen no1. Enalapril: 2.5-5 mg once or twice daily, PO, increased up to 40 mg/day every 1-2 weeks in 2.5 mg intervals.
** IV : 1.25 mg/dose every 6 hours
** Preffered regimen no 2: Lisinopril: PO, Initial 10 mg daily (no diuretic) or 5 mg daily (if on diuretic). dose range: 10-40 mg daily.
* [[Angiotensin receptor blocker]] ([[ARBs]]).<ref name="book">{{cite book |last= Kasper |first=Dennis |date=2015 |title=Harrison's Principles of Internal Medicine |url= |location= New York, New York |publisher= McGraw-Hill |page= |isbn=0071802150}}</ref><ref name="pmid26928912">{{cite journal |vauthors=Chamberlain JJ, Rhinehart AS, Shaefer CF, Neuman A |title=Diagnosis and Management of Diabetes: Synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes |journal=Ann. Intern. Med. |volume=164 |issue=8 |pages=542–52 |year=2016 |pmid=26928912 |doi=10.7326/M15-3016 |url=}}</ref>
** Preffered regimen :Losartan PO 50 mg once daily, dose can be increased to 100 mg once daily based on blood pressure response.


===Lifestyle Modifications===
===Lifestyle Modifications===
Line 25: Line 16:
*Reduction of salt and alcohol intake
*Reduction of salt and alcohol intake
*Limiting protein intake to less than 0.8 g per kg per day
*Limiting protein intake to less than 0.8 g per kg per day
===Glycemic Control===
* Glycemic control is effective in reducing the microvascular complications of [[diabetes mellitus]], as well as lowering the incidence of [[microalbuminuria]] and [[macroalbuminuria]]. In general, an [[HbA1c]] of less than 7.0% is considered adequate glycemic control.
* However, very tight glycemic control (i.e: [[HbA1c]] levels of less than 6.0% is associated with an increased mortality and [[cardiovascular disease]]. [[Anti-diabetic drug|Anti-diabetic drugs]] and injectable [[insulin analog]]s should be used to maintain normoglycemia.
* While a strict glycemic control reduces the rate at which microalbuminura appears and progress in patients with both type I and type II [[diabetes mellitus]], it is debatable as to whether or not an improved blood [[glucose]] control halts the progression of renal disease once [[microalbuminuria]] is present.<ref name="pmid8487827">{{cite journal |vauthors=Nathan DM |title=Long-term complications of diabetes mellitus |journal=N. Engl. J. Med. |volume=328 |issue=23 |pages=1676–85 |year=1993 |pmid=8487827 |doi=10.1056/NEJM199306103282306 |url=}}</ref><ref name="pmid11948275">{{cite journal |vauthors=Remuzzi G, Schieppati A, Ruggenenti P |title=Clinical practice. Nephropathy in patients with type 2 diabetes |journal=N. Engl. J. Med. |volume=346 |issue=15 |pages=1145–51 |year=2002 |pmid=11948275 |doi=10.1056/NEJMcp011773 |url=}}</ref><ref name="pmid25342915">{{cite journal |vauthors=Lim AKh |title=Diabetic nephropathy - complications and treatment |journal=Int J Nephrol Renovasc Dis |volume=7 |issue= |pages=361–81 |year=2014 |pmid=25342915 |pmc=4206379 |doi=10.2147/IJNRD.S40172 |url=}}</ref><br>
Certain [[anti-diabetic drug|anti-diabetic drugs]] have additional benefits in addition to lowering blood [[glucose]] levels. These include:<ref name="pmid25342915">{{cite journal |vauthors=Lim AKh |title=Diabetic nephropathy - complications and treatment |journal=Int J Nephrol Renovasc Dis |volume=7 |issue= |pages=361–81 |year=2014 |pmid=25342915 |pmc=4206379 |doi=10.2147/IJNRD.S40172 |url=}}</ref>
*[[Peroxisome proliferator-activated receptor|PPAR-ɣ inhibitors]], such as [[pioglitazone]] and [[rosiglitazone]] have anti-fibrotic and [[anti-inflammatory]] effects
*R[[rosiglitazone|osiglitazone]].
** Starting dosage: '''4 mg PO qd or bid'''
** For patients who respond inadequately following 8 to 12 weeks of treatment, as determined by reduction in fasting plasma glucose (FPG), the dose may be increased to '''8 mg daily'''. Increases in the dose of rosiglitazone should be accompanied by careful monitoring for adverse events related to fluid retention. Rosiglitazone may be taken with or without food.
*[[DPP-4 inhibitors]], such as [[sitagliptin]] has [[anti-inflammatory]] and anti-apoptotic properties. When [[sitagliptin]] is used for 6 months in patients with type II [[DM]], it reduces the rate of albuminuria in these patients.<ref name="pmid24843780">{{cite journal |vauthors=Mori H, Okada Y, Arao T, Tanaka Y |title=Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus |journal=J Diabetes Investig |volume=5 |issue=3 |pages=313–9 |year=2014 |pmid=24843780 |pmc=4020336 |doi=10.1111/jdi.12142 |url=}}</ref>
*SGLT-2 inhibitors decrease the rate of hyperfiltration by exerting an effect on [[tubuloglomerular feedback]].<ref name="pmid24334175">{{cite journal |vauthors=Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, von Eynatten M |title=Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus |journal=Circulation |volume=129 |issue=5 |pages=587–97 |year=2014 |pmid=24334175 |doi=10.1161/CIRCULATIONAHA.113.005081 |url=}}</ref><ref name="NEJM">{{cite journal |last=Anders |first=Hans‐Joachim |last2=Davis |first2=John M. |last3=Thurau |first3=Klaus |date=2016 |title=Nephron Protection in Diabetic Kidney Disease |url= |journal=The New England Journal of Medicine |volume=375 |issue=21 |pages=2096-2098 |doi=10.1056/NEJMcibr1608564 |access-date= }}</ref>
*Drugs such as [[metformin]] and [[sulfonylureas]] are contraindicated in advanced renal insufficiency.<ref name="book">{{cite book |last= Kasper |first=Dennis |date=2015 |title=Harrison's Principles of Internal Medicine |url= |location= New York, New York |publisher= McGraw-Hill |page= |isbn=0071802150}}</ref>


===Blood Pressure Control===
===Blood Pressure Control===

Latest revision as of 13:04, 16 June 2022

Diabetic nephropathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Diabetic nephropathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Diabetic nephropathy medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Diabetic nephropathy medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Diabetic nephropathy medical therapy

CDC on Diabetic nephropathy medical therapy

Diabetic nephropathy medical therapy in the news

Blogs on Diabetic nephropathy medical therapy

Directions to Hospitals Treating Diabetic nephropathy

Risk calculators and risk factors for Diabetic nephropathy medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dima Nimri, M.D. [2]

Overview

The goals of treatment are to slow the progression of kidney damage and control related complications. The main treatment, once proteinuria is established, is ACE inhibitor drugs, which usually reduce glomerular hypertension, proteinuria levels, systemic hypertension and slow the progression of diabetic nephropathy.

Medical Therapy

See Diabetic nephropathy secondary prevention

Lifestyle Modifications

The management of diabetic nephropathy depends a lot on lifestyle and dietary modifications.These include:[1]

Blood Pressure Control

Blood pressure in diabetic patients with nephropathy is aimed at levels of less than 130/80.[1][2][3]

Lipid Therapy

Dialysis

  • Dialysis may be necessary once end-stage renal disease develops.

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 Remuzzi G, Schieppati A, Ruggenenti P (2002). "Clinical practice. Nephropathy in patients with type 2 diabetes". N. Engl. J. Med. 346 (15): 1145–51. doi:10.1056/NEJMcp011773. PMID 11948275.
  2. ↑ "American Diabetes Association Clinical Practice Recommendations 2001". Diabetes Care. 24 Suppl 1: S1–133. 2001. PMID 11403001.
  3. ↑ Meltzer S, Leiter L, Daneman D, Gerstein HC, Lau D, Ludwig S, Yale JF, Zinman B, Lillie D (1998). "1998 clinical practice guidelines for the management of diabetes in Canada. Canadian Diabetes Association". CMAJ. 159 Suppl 8: S1–29. PMC 1255890. PMID 9834731.
  4. ↑ 4.0 4.1 4.2 4.3 Lim A (2014). "Diabetic nephropathy - complications and treatment". Int J Nephrol Renovasc Dis. 7: 361–81. doi:10.2147/IJNRD.S40172. PMC 4206379. PMID 25342915. Vancouver style error: initials (help)
  5. ↑ 5.0 5.1 5.2 Chamberlain JJ, Rhinehart AS, Shaefer CF, Neuman A (2016). "Diagnosis and Management of Diabetes: Synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes". Ann. Intern. Med. 164 (8): 542–52. doi:10.7326/M15-3016. PMID 26928912.
  6. ↑ "Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group". Lancet. 352 (9131): 854–65. 1998. PMID 9742977.
  7. ↑ Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Hallé JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S (2001). "Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals". JAMA. 286 (4): 421–6. PMID 11466120.


Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Diabetic_nephropathy_medical_therapy&oldid=1726043"